DRUG DISCOVERY AND DEVELOPMENT 31
Assay platforms and analysis techniques help pinpoint drug candidates
New assay platforms and analysis techniques are increasing the speed and sample throughput for likely new drug candidates. Sean Ottewell reports.
Les nouvelles plateformes de dosage et techniques d’analyse sont en train d’augmenter la vitesse et le débit de l’échantillon pour les médicaments candidats potentiels. Un article de Sean Ottewell.
Durch neue Assay-Plattformen und Analysetechniken werden die Geschwindigkeit und der Probendurchsatz für voraussichtliche Arzneimittelkandidaten verbessert. Sean Ottewell berichtet.
F
orteBio, a division of Pall Life Sciences and a supplier of instrumentation for
accelerated drug discovery and development, has launched the Octet HTX system – the new flagship member of the Octet line of label-free interaction analysis systems. Te new system addresses the acute industry need for increased analysis speed and sample throughput when characterising large numbers of therapeutic candidates.
Octet systems provide novel insights into drug-target binding interactions, insights that are
used to fine-tune the affinity and specificity of drug molecules. Te Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously (Fig. 1), a capability offered by no other stand-alone label-free platform, according to the company.
Te system offers dramatic time savings for researchers studying large panels of drug candidates, and provides innovative data analysis tools for developers of monoclonal antibodies and other biotherapeutic entities. In addition, the Octet HTX performs full 96-well plate determinations of protein concentrations in as little as two minutes.
“Te need for higher analytical throughput is a central theme with our pharmaceutical and biopharm customers,” noted Robert Wicke, general manager at Pall’s ForteBio division. “We believe researchers will be delighted by the Octet HTX
system. Te HTX system was engineered for speed while maintaining peak performance, and will directly address critical bottlenecks in the drug development process.”
Te BioSeek division of DiscoveRx says it also has released an industry first – a primary human cell-based assay platform for oncology research. Consisting of primary human cell-based tumour-host model systems, this new BioMAP panel enables researchers to easily assess the phenotypic impact of candidate compounds on tumour microenvironment biology in order to better predict in vivo drug activities and forecast potential clinical outcomes with respect to drug efficacy and safety.
“Tese oncology-focused BioMAP systems will support predictive and physiologically relevant cancer compound development from early discovery through pre-clinical development stages,” said Ellen Berg, scientific director and general manager of BioSeek. “Tey capture human tumour-host activities that can be modulated by a number of clinically relevant mono-therapies as well as drug combinations involving small molecule chemotherapeutics and biologics. Such BioMAP models recapitulate complex interactions between tumour cells, stromal and/or vascular tissue and recruited, infiltrating immune cells to the tumour.”
Despite a fair number of cancer drugs gaining approval for clinical use, late-stage compound attrition still remains a major issue in anticancer drug development. A critical need remains for pre-clinical models that can serve as better predictors of success in clinical trials.
Fig. 1. The Octet HTX instrument performs kinetic analysis of up to 96 binding interactions simultaneously.
Scientific evidence is mounting that combination therapies
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92